News | August 24, 2010

Research Shows Major Dose Reduction in Positron Emission Mammography

August 24, 2010 - In a recent study presented at the American Association of Physicists in Medicine (AAPM) 52nd Annual Meeting, researchers at the University of Washington showed that 18FDG dose for Positron Emission Mammography (PEM) may be reduced by as much as 70 percent without altering image quality.

PEM scanners show the location as well as the metabolic phase of a lesion. The metabolic view assists physicians to make the optimal cancer care decision by providing an unprecedented ability to distinguish between benign and malignant lesions, what researchers term specificity.

PEM is different from x-ray mammography in that it is currently not used as a screening modality. Rather, it is deployed to confirm extent of disease in a patient already diagnosed with a primary breast cancer.

"PEM is used in women with known breast cancer in order to plan treatment," said Wendie Berg, M.D., breast imaging radiologist, Lutherville, Md. "Radiation for treatment of breast cancer uses doses which are roughly 5,000 times higher than a diagnostic PEM study. Minimizing radiation dose is still important for any patient, and we can likely cut the dose of PEM in half, but the benefit to proper treatment exceeds the still low risk from the radiation dose of PEM."

Lawrence MacDonald, research assistant professor in the department of radiology at the University of Washington, and his team presented results of a study to detect lesions with very low doses of radiation using the Naviscan PEM scanner.

Preliminary results using phantom images suggest that PEM lesion detection can be reduced down to approximately 3 mCi injected dose of 18FDG or three to four times lower than the dose commonly used in clinical practice, while maintaining lesion detectability.

"Naviscan believes that the radiation dose to patients who undergo PEM can be cut at least in half, if not more, as suggested by the University of Washington study," said Judy Kalinyak, M.D., medical director, Naviscan Inc. "Our site in Japan is already injecting 5 mCi of FDG compared to the 10 mCi in the U.S., and a recently published abstract in The Journal of Nuclear Medicine further validates the reduction in dose down to 5 mCi."

Results from a recent presentation at the Society of Nuclear Medicine on findings from a National Institute of Health (NIH)-sponsored clinical study comparing PEM with breast magnetic resonance imaging (MRI) further demonstrate PEM's clinical appropriateness.

This multi-site study of hundreds of women with newly diagnosed breast cancer shows that PEM demonstrated a six percent improvement in specificity at comparably high sensitivity, and also recommended fewer unnecessary biopsies. These results are particularly significant for women who cannot tolerate an MRI exam and require an alternate imaging tool. The study is slated for publication in the December issue of the journal Radiology.

For more information: www.naviscan.com

Related Content

Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Breast Density Advocate Nancy M. Cappello Passes Away

Nancy Cappello. Image courtesy of AreYouDense.org.

News | Breast Density | November 15, 2018 | Jeff Zagoudis, Associate Editor
Imaging Technology News extends its condolences to the family, friends and colleagues of Nancy M. Cappello, Ph.D., who...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....